Table 4.
Prediction performance of IHC-immune signature, IMPRS, and clinicopathological-based model in all patient cohort.
| Discovery cohort | Validation cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| C-index (95%CI) | AUC at 3 years (95%CI) | iAUC | iBS | C-index (95%CI) | AUC at 3 years (95%CI) | iAUC | iBS | |
| IHC-immune signature | 0.824 (0.815–0.833) | 0.858 (0.779–0.938) | 0.818 | 0.138 | 0.708 (0.694–0.722) | 0.774 (0.688–0.861) | 0.617 | 0.150 |
| TNM staging system | 0.786 (0.776–0.796) | 0.810 (0.731–0.888) | 0.778 | 0.122 | 0.646 (0.626–0.666) | 0.653 (0.523–0.783) | 0.651 | 0.145 |
| Clinicopathologic-based model | 0.814 (0.805–0.823) | 0.827 (0.754–0.900) | 0.792 | 0.117 | 0.674 (0.657–0.691) | 0.694 (0.576–0.812) | 0.663 | 0.142 |
| IMPRS | 0.869 (0.861–0.877) | 0.893 (0.826–0.961) | 0.869 | 0.093 | 0.731 (0.717–0.745) | 0.785 (0.694–0.877) | 0.701 | 0.132 |
IMPRS, immune-based prognostic risk score; IHC, immunohistochemistry; CI, confidence interval; iAUC, the integrated area under the ROC curve; iBS, the integrated Brier score.